Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.
- ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.
- "Anemia and IBD affect large patient populations that are in urgent need of efficacious and safe drugs," said Feng Ren, Ph.D., CSO of Insilico Medicine.
- Empowered by its AI-based platform, Chemistry42, Insilico Medicine synthesized and tested approximately 115 compounds in total and discovered both PCCs within 12 months of project initiation.
- "It took 12 months from program initiation to the nomination of preclinical candidates, including the completion of supporting animal studies for both anemia and IBD, demonstrating the power of Insilico's AI platform."